IGF-1 LR3's insulin-mimetic pathway bypasses pancreatic feedback, meaning your body won't secrete glucagon to raise blood glucose naturally
Complete your purchase quickly and securely with a single click
Semaglutide is a medication primarily used to manage type 2 diabetes, but it has recently gained attention for its effectiveness in weight management
Understanding whether you carry variants associated with altered GLP-1 receptor sensitivity or appetite-regulation differences can support a more informed discussion about semaglutide candidacy, ideal dosing strategies, and whether combination approaches might be beneficial
While lower doses generally produce fewer adverse effects, the long-term consequences of chronic low-level GLP-1 receptor activation have not been studied in isolation
Studies from the STEP trials demonstrated average weight loss of 1522% with semaglutide over 68 weeks, driven primarily by reduced food intake rather than metabolic acceleration
